A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
Nie W, Qian J, Xu MD, Gu K, Qian FF, Hu MJ, Lu J, Gan L, Zhang XY, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Hu F, Li CH, Zhong H, Han BH.
Nie W, et al.
Oncoimmunology. 2020 Feb 20;9(1):1731072. doi: 10.1080/2162402X.2020.1731072. eCollection 2020.
Oncoimmunology. 2020.
PMID: 32158623
Free PMC article.